Alkermes trades at $52.72 heading into its July 27 print, with short sellers retreating and analysts sharply split — the most interesting tension this week is not positioning but the widening gap between bullish targets and a fresh Underperform from Bank of America.
The analyst picture turned contentious in late June and hasn't settled since. BofA downgraded to Underperform on June 29, setting a $38 target — a full 28% below the current price. That call sits in stark contrast to most of the Street: Needham raised its target to $62 this week, JP Morgan reinstated at Neutral with a $60 target, Mizuho lifted to $65 from $53, and Wells Fargo pushed its Overweight target all the way to $65 from $44. The consensus sits at Hold with a mean target of $51.58, but that average masks real disagreement. Bulls argue the narcolepsy pipeline — particularly the OX2R agonist and the recently released long-term extension data — is undervalued relative to the commercial base. Bears, led by BofA, point to a lean sales force and the significant work still required to scale commercialization ahead of any alixorexton launch. EPS surprise ranks in the 99th percentile of the universe, and the 12-month forward EPS trajectory is elevated, but the 90-day EPS momentum factor scores just 10 out of 100 — the improvement is recent and not yet entrenched.
Positioning tells a calmer story than the analyst debate suggests. Short interest has fallen 6.2% over the past week to 10.3% of the float, continuing a steady retreat from the ~11.2% peak in early July. The borrow market is relaxed: cost to borrow runs near 0.46%, and availability is loose at 549% — roughly five-and-a-half shares available for every one currently borrowed, well above the 52-week floor of 329%. The ORTEX short score has drifted down from 64.5 on July 7 to 61.1, consistent with shorts covering rather than pressing. Options are equally quiet — the put/call ratio of 0.70 sits just above its 20-day average of 0.68, with a near-zero z-score. Neither the borrow market nor the options market is pricing in a particularly charged setup into the print.
Earnings history adds a wrinkle worth noting. The most recent prior print, in May, produced a 3.4% gain on the day and a 12% gain over the following five sessions. Before that, in April, the stock dipped 0.5% on day one and lost 1.6% over five days. The sample is thin and the two outcomes diverge sharply — not a consistent pattern in either direction.
The $27 gap between BofA's $38 bear case and Mizuho's $65 bull case is the number to watch into July 27: the print will either validate the pipeline confidence embedded in the higher targets or hand the downgrade a tangible catalyst.
See the live data behind this article on ORTEX.
Open ALKS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
Alkermes heads into its July 27 earnings date with an unusual tension: a stock up 29% in a month, a wave of analyst upgrades, and yet short sellers quietly adding to positions. The Street's direction of travel has been…
Alkermes enters the final week of June with a striking split: the stock has surged 30% in a month, analysts are chasing it higher with fresh target upgrades, yet a 10.4% short interest reading signals that a meaningful…
